JP2020517671A - 小児の障害を処置する方法 - Google Patents

小児の障害を処置する方法 Download PDF

Info

Publication number
JP2020517671A
JP2020517671A JP2019557637A JP2019557637A JP2020517671A JP 2020517671 A JP2020517671 A JP 2020517671A JP 2019557637 A JP2019557637 A JP 2019557637A JP 2019557637 A JP2019557637 A JP 2019557637A JP 2020517671 A JP2020517671 A JP 2020517671A
Authority
JP
Japan
Prior art keywords
dose
antibody
seq
weeks
pediatric patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019557637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517671A5 (cg-RX-API-DMAC10.html
Inventor
ロザリオ，マリア
エー． シェツズライン，マイケル
エー． シェツズライン，マイケル
アール． トリーム，ウィリアム
アール． トリーム，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2020517671A publication Critical patent/JP2020517671A/ja
Publication of JP2020517671A5 publication Critical patent/JP2020517671A5/ja
Priority to JP2023077997A priority Critical patent/JP2023113655A/ja
Priority to JP2026045046A priority patent/JP2026120554A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019557637A 2017-04-28 2018-04-26 小児の障害を処置する方法 Withdrawn JP2020517671A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023077997A JP2023113655A (ja) 2017-04-28 2023-05-10 小児の障害を処置する方法
JP2026045046A JP2026120554A (ja) 2017-04-28 2026-03-18 小児の障害を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
US62/492,031 2017-04-28
PCT/US2018/029579 WO2018200818A2 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077997A Division JP2023113655A (ja) 2017-04-28 2023-05-10 小児の障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2020517671A true JP2020517671A (ja) 2020-06-18
JP2020517671A5 JP2020517671A5 (cg-RX-API-DMAC10.html) 2021-06-17

Family

ID=62455814

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019557637A Withdrawn JP2020517671A (ja) 2017-04-28 2018-04-26 小児の障害を処置する方法
JP2023077997A Pending JP2023113655A (ja) 2017-04-28 2023-05-10 小児の障害を処置する方法
JP2026045046A Pending JP2026120554A (ja) 2017-04-28 2026-03-18 小児の障害を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023077997A Pending JP2023113655A (ja) 2017-04-28 2023-05-10 小児の障害を処置する方法
JP2026045046A Pending JP2026120554A (ja) 2017-04-28 2026-03-18 小児の障害を処置する方法

Country Status (13)

Country Link
US (1) US20200179486A1 (cg-RX-API-DMAC10.html)
EP (1) EP3615071A2 (cg-RX-API-DMAC10.html)
JP (3) JP2020517671A (cg-RX-API-DMAC10.html)
KR (2) KR20190141148A (cg-RX-API-DMAC10.html)
CN (1) CN110612120A (cg-RX-API-DMAC10.html)
AR (1) AR111491A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018256840A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019022268A2 (cg-RX-API-DMAC10.html)
CA (1) CA3061320A1 (cg-RX-API-DMAC10.html)
IL (1) IL270201B2 (cg-RX-API-DMAC10.html)
MX (4) MX2019012749A (cg-RX-API-DMAC10.html)
TW (2) TW202342102A (cg-RX-API-DMAC10.html)
WO (1) WO2018200818A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) * 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
EP3978530A1 (en) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
MA43755A (fr) * 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) * 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤

Also Published As

Publication number Publication date
MX2024012972A (es) 2024-11-08
KR20190141148A (ko) 2019-12-23
RU2019138312A3 (cg-RX-API-DMAC10.html) 2022-02-03
KR20250134146A (ko) 2025-09-09
IL270201B1 (en) 2026-01-01
WO2018200818A2 (en) 2018-11-01
JP2023113655A (ja) 2023-08-16
AU2018256840A1 (en) 2019-11-07
JP2026120554A (ja) 2026-07-22
WO2018200818A3 (en) 2018-12-06
IL270201B2 (en) 2026-05-01
MX2024003906A (es) 2024-04-23
EP3615071A2 (en) 2020-03-04
TW201842932A (zh) 2018-12-16
BR112019022268A2 (pt) 2020-05-19
IL270201A (cg-RX-API-DMAC10.html) 2019-12-31
MX2019012749A (es) 2020-02-03
AR111491A1 (es) 2019-07-17
US20200179486A1 (en) 2020-06-11
RU2019138312A (ru) 2021-05-28
TWI811216B (zh) 2023-08-11
WO2018200818A9 (en) 2019-01-17
TW202342102A (zh) 2023-11-01
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
CN110612120A (zh) 2019-12-24
MX2024003905A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
JP2023113655A (ja) 小児の障害を処置する方法
JP5926162B2 (ja) 炎症傷害の処置および評価
CA2597717C (en) Antibodies against cxcr4 and methods of use thereof
KR20210005169A (ko) 최적화된 항tl1a 항체
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
CN117986366A (zh) 拮抗性抗犬pd-1抗体
CN108026168A (zh) 治疗炎性疾病的方法
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
CA2824089A1 (en) Selection and treatment of subjects
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
CN119768431A (zh) Igf1r抗体
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
CN101227923A (zh) 抗-MAdCAM抗体在治疗腹部疾病及热带口炎性腹泻中的用途
WO2021236509A1 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
HK40076541A (en) Methods of administering beta7 integrin antagonists
HK40008722A (en) Methods of administering beta7 integrin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230623

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230712

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250813

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250918